CHINA PHARMA HOLDINGS, INC. (CPHI)

AI-Powered SEC Filing Analysis

Quarterly Report Filed: 2026-05-15

Key Insights

  • Revenue declined 13.4% YoY to $983,536 in Q1 2026, while gross margin improved dramatically to 29% from negative 12%, indicating better cost management but continued revenue challenges in the core business.
  • Intangible assets nearly doubled from $24.1M to $38.7M due to a significant stock issuance (25M shares for $15M), diluting existing shareholders while potentially signaling acquisition or major business expansion.
  • Operating expenses surged 125% YoY driven primarily by G&A costs ($1.2M vs $507K), resulting in a net loss of $1.14M despite gross profit improvement, suggesting operational inefficiency or one-time charges.
  • Cash position deteriorated 51% to $168K from $345K while carrying $1.47B in related-party debt and $1.93M in credit lines, raising serious liquidity concerns for a smaller reporting company with negative cash flows.
Current Report Filed: 2026-03-03

Key Insights

  • China Pharma Holdings, Inc. has entered into a technology transfer agreement to acquire the ownership of an invention patent for Prinsepia Utilis Esterol Sublingual Tablets and its preparation method.
  • The company will issue 12.6 million restricted shares of common stock, valued at $0.55 per share, to pay the $6.93 million transfer price.
  • The technology transfer agreement includes the Transferor providing relevant technical services such as product R&D, registration materials, and other support.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.